8 results about "Cyclooxygenase" patented technology

The application belongs to the technical field of wound dressings, and discloses a water-based gel dressing with antibacterial and scar prevention effects and a preparation method, wherein 3-fluoro-4-carboxyphenylboronic acid is introduced to graft chitooligosaccharide, a large number of catechol structures in tannic acid solution are combined with the phenylboronic acid bond to form a dynamic boron ester bond, and a network gel structure is formed by responding to the supermolecular forces such as hydrogen bonds, wherein the boron ester bond can be broken in response to the high ROS level of the wound microenvironment and the acidic environment caused by bacterial infection, so as to efficiently release celecoxib, a selective non-steroidal anti-inflammatory drug of cyclooxygenase-2, and the liposome of verteporfin is limited in volume and stays in the dressing for a longer time, so that the sustained and stable release can be maintained in the whole wound healing process, thereby achieving the effects of on-demand inflammation regulation and long-acting mechanical response regulation.

The application provides a whey protein hydrolysate and application thereof in preparation of anti-inflammatory, antioxidant or allergy relief related products. The preparation method has the advantages of high preparation efficiency, fast speed and sufficient hydrolysis. The whey protein hydrolysate obtained through the preparation method is of excellent quality, rich in nutrition, easy to be absorbed by the human body, and can improve the cyclooxygenase-2 inhibition rate, improve the free radical clearance rate, and relieve the kidney and liver damage caused by the body allergy, and thus has the effects of anti-inflammation, anti-oxidation and allergy relief.

The application discloses a benzofuran glycoside compound, a separation and extraction method thereof, a pharmaceutical composition and application, and the compound 1 is separated from a macleaya cordata extract. A benzofuran compound is obtained by separating and purifying a n-butanol part chemical component of a macleaya cordata root. The inhibitory activity of all separated compounds 1 on a target point cyclooxygenase-2 of an inflammatory related disease is tested, the compound 1 has good inhibitory activity on COX-2 enzyme, and the compound 1 has better binding energy with the target point protein. The compound also has good NLRP3 related inhibitory effect, can be used alone or in combination with other drugs to regulate NLRP3 related proteins, is used for treating NLRP3 related mediated diseases and / or diseases, and is used for preparing drugs for preventing or treating the diseases. The compound 1 also has better inhibitory effect on acetylcholinesterase, and can be used for treating diseases such as Alzheimer's disease, myasthenia gravis and Parkinson's disease.

This invention discloses a 7-O-7' lignan (+) / (–)-7- epi -oryzativol, its preparation method, and its applications belong to the field of pharmaceutical chemistry technology. The 7-O-7' lignan (+) / (–)-7- epi -oryzativol has the structure shown in formula C. This class of compounds was first obtained from Artemisia bulbifera (… Laportea bulbifera The compound was isolated from (+) / (–)-7- epi -oryzativol exhibits significant inhibitory activity against cyclooxygenase-2 (COX-2), and compound (+)-7- epi -oryzativol has a high COX-2 selectivity index and exhibits significant anti-inflammatory effects, making it suitable for use in the preparation of anti-inflammatory drugs.

This invention relates to the field of pharmaceutical technology, providing memantine derivatives, their preparation methods, and their application in the preparation of drugs for treating soluble cyclooxygenase-mediated diseases. The memantine derivatives provided by this invention have typical urea or amide structures. The urea and amide structures serve as the primary pharmacophores of sEH (hydrophobic epoxide hemoglobin). The memantine moiety, as a hydrophobic segment, interacts with the receptor hydrophobically. Molecular docking shows that the memantine moiety, as a hydrophobic segment, interacts with the receptor hydrophobically, particularly when both R1 and R2 are methyl groups, which enhances the van der Waals forces. Therefore, the memantine derivatives provided by this invention exhibit high inhibitory activity against human (HsEH) and murine sEH (MsEH), and can be used as sEH inhibitors in the preparation of drugs for treating soluble cyclooxygenase-mediated diseases, showing broad application prospects.

This invention relates to a novel application of all-trans retinoic acid combined with a cyclooxygenase inhibitor in the treatment of prostate cancer. The all-trans retinoic acid is used to regulate gene expression and metabolic processes in tumor cells, promoting cell differentiation and tumor suppressor signaling pathways. The cyclooxygenase inhibitor is used to inhibit prostaglandin production induced by all-trans retinoic acid treatment. The cyclooxygenase inhibitor includes small molecule compounds that specifically inhibit / antagonize cyclooxygenase, interfering molecules that specifically interfere with cyclooxygenase gene expression, gene-editing reagents that specifically knock out the cyclooxygenase gene, reagents that downregulate / lose the function of cyclooxygenase, or antibodies that specifically bind to cyclooxygenase. The advantages are: it reveals that the combination of all-trans retinoic acid and a cyclooxygenase inhibitor reduces the immunosuppressive microenvironment in the tumor during prostate cancer treatment, thereby enhancing the tumor-suppressive effect and strengthening anti-tumor immunity.